Sunday, November 8, 2026

Haitong Buys NOVO BANCO Investment Bank (BESI)

Chinese brokerage Haitong Securities completed its €379 million acquisition of Novo Banco's investment banking arm (BESI) on September 7, 2015. The deal was approved by the Bank of Portugal and the European Commission.

LM Salvado
LM Salvado

September 8, 2015

Novo Banco - Image Credit João Ramos
On September 7, 2015, Haitong bought Novo Banco investment bank for the December 2014 agreed value of 379 million Euros ($425 million). In December 2014, talks between Novo Banco and the Chinese brokerage Haitong Securities Ltd company closed with a possible future sale of the BES Investment Bank for 379 million Euros ($425 million). The sale has since then been approved by the Bank of Portugal, the European Commission and other supervising authorities.

About Novo Banco and BESI

In August 2014, after a state rescue, the Portuguese bank “Novo Banco” was carved out as the “good bank” from the Banco Espirito Santo (BES) bank. The bank crumbled under the weight of the debts built up by the bankruptcy of the Espirito Santo Group. Unconfirmed rumors point to a possible change of the BESI headquarters over to London and the abandonment of the “Espirito Santo” reference related to the previous shareholder's family name. According to José Maria Ricciardi, the former BESI appointed Director, "BESI will be a strategic bank to the EMEA [Europe, Middle East, and Africa] and the Americas." BESI business plan for the next three years expects up to 1.5 billion Euros capital raise, which could occur through various operations including possible future acquisitions.
LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com